BRPI0921888A2 - terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase - Google Patents

terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase

Info

Publication number
BRPI0921888A2
BRPI0921888A2 BRPI0921888A BRPI0921888A BRPI0921888A2 BR PI0921888 A2 BRPI0921888 A2 BR PI0921888A2 BR PI0921888 A BRPI0921888 A BR PI0921888A BR PI0921888 A BRPI0921888 A BR PI0921888A BR PI0921888 A2 BRPI0921888 A2 BR PI0921888A2
Authority
BR
Brazil
Prior art keywords
inhibitor
combination therapy
egfr
kinase
kinase inhibitor
Prior art date
Application number
BRPI0921888A
Other languages
English (en)
Inventor
Sandaruwan Geeganage
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0921888A2 publication Critical patent/BRPI0921888A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BRPI0921888A 2008-11-11 2009-11-04 terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase BRPI0921888A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11327608P 2008-11-11 2008-11-11
PCT/US2009/063189 WO2010056575A1 (en) 2008-11-11 2009-11-04 P70 s6 kinase inhibitor and egfr inhibitor combination therapy

Publications (1)

Publication Number Publication Date
BRPI0921888A2 true BRPI0921888A2 (pt) 2015-12-29

Family

ID=41664868

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921888A BRPI0921888A2 (pt) 2008-11-11 2009-11-04 terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase

Country Status (11)

Country Link
US (1) US8334293B2 (pt)
EP (1) EP2355821A1 (pt)
JP (1) JP2012508240A (pt)
KR (1) KR20110075015A (pt)
CN (1) CN102209538B (pt)
AU (1) AU2009314336B2 (pt)
BR (1) BRPI0921888A2 (pt)
CA (1) CA2743295A1 (pt)
EA (1) EA018624B1 (pt)
MX (1) MX2011005002A (pt)
WO (1) WO2010056575A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370448B (es) * 2013-03-11 2019-12-13 Merck Patent Gmbh Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa.
US20140255471A1 (en) 2013-03-11 2014-09-11 Wake Forest University Health Sciences Method of treating brain tumors
US9457019B2 (en) * 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
CA2943402C (en) * 2014-04-04 2022-12-13 Astrazeneca Ab Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer
US11806326B2 (en) 2018-01-29 2023-11-07 Jonathan Sackner-Bernstein Methods for dopamine modulation in human neurologic diseases
DE102018205152A1 (de) 2018-04-05 2019-10-10 Glatt Ingenieurtechnik Gmbh Verfahren und Reaktor zur Herstellung von Partikeln

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295415A1 (en) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
ATE543821T1 (de) 2004-12-28 2012-02-15 Exelixis Inc Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
EP1946120A2 (en) 2005-10-18 2008-07-23 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
EA018624B1 (ru) 2013-09-30
US20110207752A1 (en) 2011-08-25
AU2009314336B2 (en) 2013-09-12
EP2355821A1 (en) 2011-08-17
US8334293B2 (en) 2012-12-18
EA201170682A1 (ru) 2011-10-31
CN102209538B (zh) 2013-06-12
KR20110075015A (ko) 2011-07-05
AU2009314336A1 (en) 2010-05-20
MX2011005002A (es) 2011-05-25
CN102209538A (zh) 2011-10-05
CA2743295A1 (en) 2010-05-20
JP2012508240A (ja) 2012-04-05
WO2010056575A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
CY2019027I1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
CY2020023I1 (el) Αναστολεiς βητα-λακταμασων
CY2019009I1 (el) Αναστολεις πρωτεϊνικων κινασων
BRPI0716781A2 (pt) Inibidores da quinase
BRPI0811212A2 (pt) Inibidores de p70 quinase
ATE522535T1 (de) Pyrrolotriazin-kinasehemmer
BRPI0910668A2 (pt) inibidores de proteína quinases
BRPI0817843A2 (pt) Inibidores da quinase c-fms
BRPI0810086A2 (pt) inibidores de tirosina quinase de bruton
BRPI1009112A2 (pt) inibidores de tirosina quinase de bruton
BRPI0820544A2 (pt) 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI1011129A2 (pt) métodos e compostos inibidores de janus cinase
ATE519763T1 (de) Pyrrolopyrazin-kinasehemmer
BRPI0922880A2 (pt) compostos inibidores de quinase
BRPI0921916A2 (pt) inibidores de akt e p70 s6 quinase
DK2116775T3 (da) Kogesektion
BRPI0918564A2 (pt) inibidores
DK2318378T3 (da) Quinazolin-derivater
BRPI0921509A2 (pt) inibidor triazolotiadiazol de proteína quinase c-met
BRPI0716198A2 (pt) Pirrolo-isoquinolinas como inibidores de cinase
BRPI0921888A2 (pt) terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase
DE112009004416A5 (de) Kombinationsleuchte
DK2170891T3 (da) Pyrazolopyrimidinon-kinasehæmmere
ITTO20080468A1 (it) Termoconvettore

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2376 DE 19-07-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.